Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN Pre-Tax Margin
Income before tax as a percentage of revenue.
Guardian Pharmacy Services, Inc.NYSE: GRDN
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin widens to 8.5%
Pre-tax margin was 8.5% in Q2 FY2026, up 4.8 pp from a year earlier. On a trailing-twelve-month basis it was 6.5%, up 11.4 pp year over year. Over 3 fiscal years it narrowed by 0.4 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 5.1%
- Year-over-year change
- +10.5pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.1% | +10.5pp |
| FY2024 | 2024-12-31 | -5.4% | -9.0pp |
| FY2023 | 2023-12-31 | 3.6% | -1.9pp |
| FY2022 | 2022-12-31 | 5.5% | +1.9pp |
| FY2021 | 2021-12-31 | 3.6% | — |
Pre-Tax Margin vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 pre-tax margin of 6.5% is the 3rd highest of the 10 companies compared; the peer median is -31.8%.
- Its year-over-year change of +11.4 pp is the 4th highest of 10, against a peer median of +0.9 pp.
- Over three fiscal years its change of -0.4 pp compares with a peer median of +16.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 10.4% | -0.2 pp | +7.2 pp | |
| LTM Sep 2026 | 9.5% | +0.4 pp | +8.2 pp | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | 6.5% | +11.4 pp | -0.4 pp |
| LTM Sep 2026 | -10.5% | +0.9 pp | +25.2 pp | |
| LTM Sep 2026 | -28.4% | -8.0 pp | +54.6 pp | |
| LTM Mar 2026 | -31.8% | +4.4 pp | +85.2 pp | |
| LTM Mar 2026 | -44.3% | -32.0 pp | -63.1 pp | |
| LTM Jun 2026 | -47.5% | +544.5 pp | +1047.2 pp | |
| LTM Jun 2026 | -88.2% | +1325.2 pp | — | |
| LTM Mar 2026 | -529.7% | +303.0 pp | -404.0 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding GRDN) | -31.8% | +0.9 pp | +16.7 pp | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 792.07M | 908.91M | 1.05B | 1.23B | 1.45B |
| Cost of Revenue | 630.81M | 723.04M | 837.88M | 984.04M | 1.17B |
| Gross Profit | 161.27M | 185.87M | 208.31M | 244.37M | 282.04M |
| Gross Margin | 20.4% | 20.4% | 19.9% | 19.9% | 19.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Operating Expenses | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| EBITDA | 46.49M | 68.15M | 58.81M | (43.43M) | 96.42M |
| EBITDA Margin | 5.9% | 7.5% | 5.6% | -3.5% | 6.7% |
| Operating Income | 30.15M | 51.99M | 40.95M | (62.92M) | 88.91M |
| Operating Margin | 3.8% | 5.7% | 3.9% | -5.1% | 6.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.64M | 1.93M | 2.86M | 3.28M | 665K |
| Other Income / Expenses | (1.82M) | (2.33M) | (3.23M) | (3.56M) | (15.49M) |
| Income Before Tax | 28.33M | 49.66M | 37.72M | (66.48M) | 73.42M |
| Pre-Tax Margin | 3.6% | 5.5% | 3.6% | -5.4% | 5.1% |
| Income Tax Expense | 0 | 0 | 0 | 4.56M | 24.47M |
| Net Income | 16.31M | 35.42M | 23.9M | (87.29M) | 49.22M |
| Net Margin | 2.1% | 3.9% | 2.3% | -7.1% | 3.4% |
| EPS (Basic) | 0.27 | 0.58 | 0.39 | (1.77) | 0.79 |
| EPS (Diluted) | 0.27 | 0.58 | 0.39 | (1.77) | 0.78 |
| Weighted Avg Shares | 60.84M | 60.84M | 60.84M | 62.01M | 62.39M |
| Weighted Avg Shares (Diluted) | 60.84M | 60.84M | 60.84M | 62.01M | 63.3M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.